Retrophin

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Retrophin, Inc. (RTRX) CEO Eric Dube on Q2 2019 Results - Earnings Call Transcript

Retrophin (RTRX) delivered earnings and revenue surprises of -48.72% and 4.79%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Retrophin (RTRX) Reports Q2 Loss, Tops Revenue Estimates

Notorious "pharma bro" Martin Shkreli has reached a settlement with his former biopharmaceutical company Retrophin just weeks ago after he sued two company directors and its ex-general counsel from prison. Shkreli has dismissed his suit.

'Pharma bro' Shkreli settles case with Retrophin weeks after suing drug firm's directors from prison

Retrophin, Inc. (RTRX) CEO Eric Dube on Q1 2019 Results - Earnings Call Transcript

Retrophin (RTRX) delivered earnings and revenue surprises of -75.00% and -5.72%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Retrophin (RTRX) Reports Q1 Loss, Misses Revenue Estimates

Aphria

These two growth stocks are poised for enormous gains.

2 Healthcare Stocks With Jaw-Dropping Growth Potential

News for Retrophin Stock (RTRX)